分子反应宣布转化的关键协议肿瘤学oncom制成药品

oncom制成是一个私有的临床开发阶段生物制药公司开发治疗目标生物通路关键肿瘤启动细胞,也被称为“癌症干细胞。”Under the terms of the agreement, the collaboration will deliver molecularly characterized PDX models for multiple cancer indications, with full utilization of Molecular Response's highly optimized pre-screening and characterization methodologies. This will allow OncoMed to expand their already extensive bank of proprietary xenograft models derived from freshly resected human cancers based on the molecular profile of the tumors as well as complement OncoMed's existing biomarker and patient selection efforts. Financial terms of the collaboration were not disclosed.

“肿瘤的扩张银行在这种选择性的方式将增强我们的努力发展预测生物标志物与我们的抗癌干细胞疗法的发展,”Paul Hastings说,总裁兼首席执行官oncom制成的药品。

PDX特征模型的“发展是一个自然的除了我们的核心竞争力在处理patient-derived原发肿瘤细胞。oncom制成一个领导者在癌症干细胞疗法和最挑剔的伙伴评估新的PDX模式。扩大与oncom制成合作是我们成功的证明,继续致力于使进一步评估癌症疗法更好的特征模型与使用高含量的细胞平台和独家patient-derived原发肿瘤细胞库,”首席执行官赛勒斯k . Mirsaidi说,分子反应。